TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Roche Tops the Swiss Market After First Quarter Sales Beat Expectations
Play
INVESTING

Roche Reports Phase 3 Progress for Its Covid Pneumonia Treatment

Here’s What to Watch at the World Economic Forum in Davos
MARKETS

U.S.-China Tensions Flare Anew, Buffett Dumps Airlines, FDA OKs Roche Antibody Test - 5 Things You Must Know Monday

Roche Lifts Full-Year Outlook After Solid Q2 Earnings Beat
LATEST NEWS

Roche Gets Emergency OK for Coronavirus Antibody Test

Novartis Lead
INVESTING

Novartis to Test Anti-Malaria Drug as Potential Coronavirus Treatment

Coronavirus Lockdown Lead
HEALTH

Coronavirus Latest Updates: A Timeline of Recent Events

Jim Cramer: We Remain Excited About Abbott Laboratories for Action Alerts Plus
INVESTING

Abbott Labs Gets FDA Emergency Nod for Coronavirus Tests

Jim Cramer: Stay Long Thermo Fisher, Sell FEI
INVESTING

Thermo Fisher Garners FDA Emergency Nod for Coronavirus Test

It's Time to Stop Comparing Tim Cook to Steve Jobs. Says Jim Cramer
TECHNOLOGY

Apple Closes All Stores Outside China to Combat Coronavirus

US President Donald Trump signed the deal at the White House. Photo: Bloomberg
INVESTING

President Trump Declares State of Emergency to Combat Coronavirus

Roche Shares Gain; CEO 'Fully Dedicated' to Key U.S. Market
Video

Roche To Start Mass-Producing Coronavirus Tests

  • Mar 13, 2020 12:11 PM EDT
Hong Kong And Shanghai-listed Fosun Pharma Says It Has Sought Approval From Beijing For Its Coronavirus Test Kits
WORLD

Roche Gets Emergency FDA OK to Make Coronavirus Test Kits

PRESS RELEASES

FDA Grants Breakthrough Therapy Designation For Genentech's Esbriet (pirfenidone) In Unclassifiable Interstitial Lung Disease

PRESS RELEASES

FDA Grants Priority Review To Genentech's Tecentriq Monotherapy As First-line Treatment Of Certain People With Advanced Non-small Cell Lung Cancer

PRESS RELEASES

Greenphire And Roche Team To Address Critical Clinical Trial Patient Convenience Issues At 11th Annual SCOPE Summit

PRESS RELEASES

Genentech Provides Topline Results From Investigator-Led Phase II/III Trial With Gantenerumab In Rare Inherited Form Of Alzheimer's Disease

PRESS RELEASES

Genentech's Risdiplam Showed Significant Improvement In Motor Function In People Aged 2-25 With Type 2 Or 3 Spinal Muscular Atrophy

Midday Report: Biogen Lifts Biotech; U.S. Stocks Break Higher
INVESTING

Biogen Beats Q4 Estimates on Strong Sales of Treatments for MS, Spinal Atrophy

PRESS RELEASES

Genentech Submits Supplemental Biologics License Application To The FDA For Tecentriq In Combination With Avastin For The Most Common Form Of Liver Cancer

PRESS RELEASES

Genentech Provides An Update On Phase III Study Of Tecentriq In People With Muscle-invasive Urothelial Cancer

PRESS RELEASES

Genentech's Risdiplam Meets Primary Endpoint In Pivotal FIREFISH Trial In Infants With Type 1 Spinal Muscular Atrophy

PRESS RELEASES

Tamiflu Fraud Bilked $1.5 Billion From Government, Alleges Whistleblower

The Top 25 Wealthiest Families in the World
LIFESTYLE

The Top 25 Wealthiest Families in the World

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts
Video

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts Ahead of Earnings

  • Jul 12, 2019 9:30 AM EDT
Biogen Plummets as Alzheimer Drug Shows Little Efficacy in Trial
STOCKS

Biogen Drops Following Piper Jaffray Downgrade

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug
STOCKS

Spark Therapeutics' Shares Misfire on Roche Acquisition Delay